Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date

Subhabrata Moitra,1 Arvind B Bhome,2 Bill B Brashier1 1Chest Research Foundation, Pune, Maharashtra, India; 2Indian Coalition of Obstructive Lung Diseases (ICOLD) Network, Pune, Maharashtra, India Abstract: The quest for the right combination of bronchodilators with different mechanisms of action...

Full description

Bibliographic Details
Main Authors:	Moitra S, Bhome AB, Brashier BB
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-04-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/aclidinium-bromideformoterol-fixed-dose-combination-therapy-for-copd-t-peer-reviewed-article-DDDT

Similar Items

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
by: Anthony D. D’Urzo, et al.
Published: (2019-05-01)

Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
by: K. Suresh Babu, et al.
Published: (2015-04-01)

Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD
by: Ramos M, et al.
Published: (2016-09-01)

An update on the efficacy and safety of aclidinium bromide in patients with COPD
by: Khuder Alagha, et al.
Published: (2011-02-01)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
by: Watz H, et al.
Published: (2017-08-01)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
by: Matera MG, et al.
Published: (2016-01-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
by: Miravitlles M, et al.
Published: (2016-08-01)

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
by: Karabis A, et al.
Published: (2014-04-01)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01)

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
by: Sims MW, et al.
Published: (2011-09-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
by: Trudo F, et al.
Published: (2015-09-01)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
by: Jones PW
Published: (2015-03-01)

Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study
by: Shambo Samrat Samajdar, et al.
Published: (2023-01-01)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
by: Sundeep Salvi, et al.
Published: (2022-01-01)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
by: Prakash A, et al.
Published: (2015-01-01)

The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
by: François Maltais, et al.
Published: (2012-12-01)

High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
by: Massimo Corradi, et al.
Published: (2016-10-01)

Budesonide/formoterol combination in COPD: a US perspective
by: Amir Sharafkhaneh, et al.
Published: (2010-10-01)

Мometasone furoate/formoterol: new fixed-dose combination in the treatment of bronchial asthma
by: A. V. Еmelyanov
Published: (2013-12-01)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
by: Nicola A. Hanania, et al.
Published: (2020-04-01)

Efficacy of indacaterol 75 &micro;g versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
by: Cope S, et al.
Published: (2012-07-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
by: Li W, et al.
Published: (2023-11-01)

Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD
by: La Piana GE, et al.
Published: (2011-07-01)

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Asthma Control Can Be Maintained after Fixed-Dose, Budesonide/Formoterol Combination Inhaler Therapy is Stepped Down from Medium to Low Dose
by: Masayuki Hojo, et al.
Published: (2013-01-01)

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
by: Doherty DE, et al.
Published: (2012-02-01)

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
by: Tashkin DP, et al.
Published: (2012-02-01)

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
by: Monteagudo M, et al.
Published: (2017-04-01)

NEW MEDICINAL FORM IN TREATMENT OF BRONCHIAL ASTHMA: FIXED COMBINATION OF FORMOTEROL AND BECLOMETASONE
by: O.I. Simonova
Published: (2010-01-01)

NEW MEDICINAL FORM IN TREATMENT OF BRONCHIAL ASTHMA: FIXED COMBINATION OF FORMOTEROL AND BECLOMETASONE
by: O.I. Simonova
Published: (2010-05-01)

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combinations in COPD
by: Mohd Kashif Siddiqui, et al.
Published: (2019-12-01)

Nebulized formoterol: a review of clinical efficacy and safety in COPD
by: Nicholas J Gross, et al.
Published: (2010-06-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
by: Gwen S. Skloot, et al.
Published: (2023-10-01)